Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

NCT03524820 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped By Merck

Conditions

Cancer of Colon

Interventions

DRUG: Cetuximab

Sponsor

Hadassah Medical Organization

Collaborators

[object Object]